Document is current
Any future updates will be listed below
-
Authors
McElroy, Susan L.
Winham, Stacey J.
Cuellar-Barboza, Alfredo B.
Colby, Colin L.
Ho, Ada Man-Choi https://orcid.org/0000-0003-4989-8782
Sicotte, Hugues
Larrabee, Beth R.
Crow, Scott
Frye, Mark A.
Biernacka, Joanna M. https://orcid.org/0000-0001-9350-4440
- License Information
-
More Information
Article History
Received: 13 June 2017
Revised: 6 September 2017
Accepted: 13 September 2017
First Online: 2 February 2018
Conflict of interest
: Dr. S. L. Mc. E has been a consultant to or member of the scientific advisory board of Avanir, Bracket, F. Hoffmann-La Roche Ltd., MedAvante, Mitsubishi Tanabe Pharma Corporation, Myriad, Naurex, Novo Nordisk, Shire, and Sunovion. She has also been a principal or coinvestigatoron studies sponsored by Alkermes, Allergan, Azevan Pharmaceuticals, Forest, Marriott Foundation, Myriad, National Institute of Mental Health, Naurex, Novo Nordisk, Shire, Sunovion, and Takeda Pharmaceutical Company Limited. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse ControlDisorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, hasreceived payments from Johnson and Johnson, which has exclusive rights under the patent. Dr. M. A. F. has received grant support from Assurex Health, Myriad, Pfizer, Marriott Foundationand Mayo Foundation; has been a consultant to Janssen Global Services, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad, Sunovion, and Teva Pharmaceuticals; has received CME/Travel Support/presentation from CME Outfitters Inc. and Sunovion. The remaining authors declare that they have no conflict of interest.
